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Env Reveals a New Mode for VH1-2 Antibody 
Recognition of the CD4 Binding Site Relevant 
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Background: Structural studies of broadly neutralizing antibodies 
(bNAbs) bound to Env trimers have revealed mechanisms by 
which bNAbs targeting various epitopes penetrate the glycan 
shield to either accommodate or include N-glycans in their 
epitopes. Although accessibility to the conserved host receptor 
(CD4) binding site (CD4bs) is restricted by surrounding glycans, 
VRC01-class bNAbs mimic CD4 binding to share a common mode 
of gp120 binding and glycan accommodation using a VH1-2*02-
derived variable heavy (VH) domain. While attractive candidates 
for immunogen design, features of VRC01-class bNAbs such 
as a high degree of somatic hypermutation (SHM) and a short 
(5-residue) light chain (LC) complementarity determining region 
3 (CDRL3) (found in only 1% of human LCs) suggest they might 
be difficult to elicit through vaccination. However, we recently 
isolated a VH1-2*02-derived CD4bs bNAb, named IOMA, that 
includes a normal-length (8 residues) CDRL3.
Methods: We used X-ray crystallography to solve the first 
structure of a fully- and natively-glycosylated Env trimer in 
complex with IOMA, and the V3-loop-directed bNAb 10-1074.
Results: Our structure revealed antibody-vulnerable glycan 
holes and roles of complex-type N-glycans on Env that are 
relevant to vaccine design, while also demonstrating that IOMA 
is a new class of CD4-mimetic bNAb that contains features of 
both VH1-2/VRC01-class and VH1-46/8ANC131-class bNAbs.
Conclusions: Analysis of the native glycan shield on HIV-1 
Env allows the first full description of the interplay between 
heterogeneous untrimmed high-mannose and complex-type 
N-glycans within the CD4bs, V3-loop, and other epitopes on Env. 
In addition, the structural characterization of IOMA revealed 
an alternative pathway from VRC01-class bNAbs relevant to 
vaccine design, which could more readily lead to an effective 
vaccine response due to higher frequencies of normal-length 
CDRL3s compared with the rare 5-residue CDRL3s required for 
VRC01-class bNAbs, and a lower need for SHMs.
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Structure of a CH58-like V2 Antibody from 
Natural Infection Reveals Convergent Heavy 
Chain Maturation and a Novel K169 Binding 
Light Chain Motif
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Lambson1, Salim S. Abdool Karim3, Manuel Fernandes2, Yasien 
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1National Institute for Communicable Diseases (NHLS), 
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Background: K169-dependent V2 binding antibodies were a 
correlate of reduced infection risk in RV144. CH58, a V2-specific 
antibody isolated from one vaccinee competed with α4β7, and 
used a key light chain encoded CDRL2 ED-motif to bind K168/
K169. Here we determine the structure of a V2/K169 reactive 
antibody isolated from CAPRISA donor CAP228 (CAP228-16H) 
bound to a V2 peptide, and compare this to CH58.
Methods: Complexes were screened for crystal growth across 
396 conditions. The structure was solved using Phenix/Coot, 
and interactions were weighted by mutagenesis and ELISA. 
Longitudinal deep sequencing of CAP228-16H immunoglobulin 
variable regions was used to trace specific maturation pathways.
Results: Optimised crystals diffracted to 2.4Å in P212121. The V2 
conformation in both CH58 and CAP228-16H bound structures 
was strikingly similar, with residues 166-176 adopting an α helix 
and residues 177-182 an extended coil. CAP228-16H was derived 
from the same VH5-51 gene as CH58, and shared germline 
encoded contacts between its anionic CDRH2 and K/R178 in V2. 
Deep sequencing of CAP228-16H identified similar pathways of 
affinity maturation in the CDRH1 of both antibodies that formed a 
key salt bridge with residue D180 in the α4β7 binding motif. Only 
CDRH3 interactions between the two antibodies differed, in that 
CAP228-16H preferred Y173 over H173, and made contacts with 
Y177 that allowed for tyrosine sulfation, likely to occur in natural 
infection. CAP228-16H used a VL3-21 gene that does not encode 
the signature ED-motif, but still forms key V2 interactions with 
K168 and K169 via an anionic pocket formed by the germline 
CDRL2 DDSD-motif.
Conclusions: By solving the CAP228-16H crystal structure we 
identify V2-interacting signatures in the VH5-51 CDRH2, as well 
as two identical maturation pathways used by CAP228-16H 
and CH58 to contact the α4β7 binding motif. The use of VL3-
21 identifies a new CDRL2 motif able to recognise K168/K169, 
broadening the light chain germline repertoire used by RV144-
like V2 antibodies. 
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